Acta Scientific Women's Health (ASWH)(ISSN: 2582-3205)

Research Article Volume 2 Issue 3

Characteristics of Breast Cancers in Brazzaville: About 85 Cases

Ndounga E1*, Bambara AT2, Bolenga Liboko AF1, Mabiala Yvon1 and NkouaMbon JB1

1Medical Oncology Department, Teaching Hospital of Brazzaville, Republic of Congo
2Medical Oncology Department, Yalgado Ouedraogo Teaching Hospital, Ouagadougou, Burkina Faso

*Corresponding Author: Ndounga E, Medical Oncology Department, Teaching Hospital of Brazzaville, Republic of Congo.

Received: January 06, 2020; Published: February 10, 2020



Objective: To describe the epidemiological, clinical and histological characteristics of breast cancer in Brazzaville

Materials and Method: This was a retrospective study carried out in the Medical Oncology Department of the Brazzaville University Hospital between January 2013 and December 2017. All the patients followed for histological breast cancer were included. Confirmed and having benefited from immunohistochemistry for hormone receptor assay and HER 2 status.

Results: Eighty-five patients were collected. The average age of the patients was 47.4 years with extremes of 22 and 73 years. The average consultation time was 7.9 months. The main reason for consultation was the finding or persistence of a breast nodule. Nonspecific infiltrating carcinoma was the most common histological type, and one case of medullary carcinoma was found. The histopronotic grades SBR I, II and III were respectively in 15.3%, 52.9% and 30.6% of the cases. Tumors of luminal type A and triple negative were the most representative, respectively 42.4% and 38.8%; tumors over expressing HER 2 were found in 10.6% and luminal B in 8.2% of cases. The majority of patients were in stage III (57.6%), 23.5% in stage II and 10.6% in stage IV. The median survival of the patients was 17 months for stage II, 25 months for stage III and 14 months for stage IV. According to the molecular groups, the median survival was 10 months for HER 2 (+) phenotype, 18 months for luminal A and B phenotypes and 28 months for the negative triple phenotype.

Conclusion: In the republic of Congo and more precisely in Brazzaville, breast cancer management remains difficult due to the lack of effective technical facilities and medical treatments.

Keywords: Breast Cancer; Immunohistochemistry; Brazzaville



  1. Abbas F., et al. “Molecular classification of breast cancer in Morocco’. Pan African Medical Journal 13 (2012): 91-114.
  2. Abbas F., et al. “Epidemiological and Biological profile of breast cancer in Fès-Boulemane (Morocco)”. EMHJ 17.12 (2002): 930-936.
  3. Ben Ahmed S., et al. “Breast cancer prognosis in tunisian women: an analysis of a hospital trial involving 729 patients”. Santé Publique 14.3(2002): 231-241.
  4. Larsimer D., et al. “HER2 et topo-isomérase Iiα: deux marqueurs d’intérêt clinique dans le cancer du sein”. Bulletin du Cancer 95.3 (2008): 344-351.
  5. Rakha EA., et al. “The update ASCO/CAP guideline recommendations for HER 2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice”. Histopathology 64.5 (2014): 609-615.
  6. Essiben F., et al. “Diagnosis and treatment of breast cancer in Cameroon: a series of 65 cases”. Mali Medicine 18.1 (2001): 1-5.
  7. Nsondé Malanda J., et al. “Twelve years of working of Brazzaville cancer registry”. Bulletin du Cancer 100.2 (2013): 135-139.
  8. Ben Gobrane H., et al. “Breast cancer prognosis in Salah Azaiez institue of cancer, Tunis”. EMHJ 2.13 (2007): 309-318.
  9. Rafaramino F., et al. “Management of breast cancer in Madagascar”. Cancer Radioth 5 (2001): 445-451.
  10. Madany L., et al. “Breast Cancer in sub-saharan African women: review”. Bulletin du Cancer 7 (2001): 797-806.
  11. Eisinger F., et al. “Expertise collective inserm – FNCLCC : recommandations portant sur la prise en charge des femmes ayant un risque d’origine génétique de développer un cancer du sein et/ou de l’ovaire”. Bulletin du Cancer 86.3 (1999): 307-313. 
  12. Touré M., et al. “Factors linked to late diagnosis breast cancer in sub-saharan Africa: case of Ivory Coast”. Gynecology Obstetrics and Fertility 41.12 (2013): 696-700.
  13. Gombé Mbalawa C., et al. “Arrival of patients at advanced stage: tempting to identify responsibility”. Bulletin du Cancer 100.2 (2013): 167-172.
  14. Elston CW and Ellis IO. “Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up”. Histopathology 19 (1991): 403-410.
  15. Aloulou S., et al. “Facteurs liés au diagnostic tardif du cancer du sein : expérience du CHU Mohammed VI Marrakech”. Pan African Medical Journal 21 (2015): 162-166.
  16. Aksim M., et al. “Cancer du sein : étude des facteurs histopronostiques (à propos de 239 cas”. Rev Maroc Cancer 4.1 (2013): 41-45.
  17. Sotiriou C., et al. “Gene expression profiling in breast cancer: understanding the molecul arb as is of histologic grade to improve prognostic”. Journal of the National Cancer Institute 98 (2006): 262-272.
  18. Nalwoga H., et al. “Expression of EGFR and c-kit is associated with the basal-like phénotype in breast cancer of african women”. APMIS 116 (2008): 515-525.
  19. Hou D., et al. “Population différences in breast cancer: survey in indigenous african women reveals over representation of triple negative breast cancer”. Journal of Clinical Oncology 27 (2009): 4515-4521.
  20. Bird PA., et al. “Poor hormone receptor expression in East African breast cancer: évidence of biologically different disease?” Annals of Surgical Oncology 19 (2008): 1983-1988. 
  21. Gueye SMK., et al. “Issues involving breast cancer management in Senegal: a cross-sectional study”. Pan African Medical Journal 25.3 (2016): 1-5.
  22. Cottu PH. “Systemic neoadjuvant therapy of luminal breast cancer in 2016”. Bulletin du Cancer 104.1 (2017): 69-78.
  23. Liedtke C., et al. “Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer”. Journal of Clinical Oncology 26.8 (2008): 1275-1281.
  24. Didi-Kouko Coulibaly J., et al. “Prévalence des récepteurs hormonaux et de HER2 dans le cancer du sein au service de Cancérologie du CHU de Treichville. Résultats préliminaires”. Bulletin du Cancer 95.9 (2008): 799-803.
  25. Menard S., et al. “HER2+breast carcinomas as a particular subset with pelicular clinical behaviour”. Clinical Cancer Research 8 (2002): 520-525.
  26. POLITE NB., et al. “Racial différences in clinical outcomes from metastatic breast cancer: a polled analysis of GALGB 9342 and 9840-cancer and leukemia Group B”. Journal of Clinical Oncology 26 (2008): 2659-2665.


Citation: Ndounga E., et al. “Characteristics of Breast Cancers in Brazzaville: About 85 Cases”. Acta Scientific Women's Health 2.3 (2020): 11-17.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US